International Stem Cell CORP·4

Jun 23, 8:31 PM ET

Don Wright 4

Research Summary

AI-generated summary

Updated

International Stem Cell (ISCO) Director Don Wright Receives Award

What Happened
Don Wright, a director of International Stem Cell Corp (ISCO), was granted two derivative awards on June 11, 2026: 30,000 shares and 182,584 shares (total 212,584). Both grants are reported at $0.00 per share on the Form 4 (derivative/award status), meaning they are awards or options rather than an open‑market purchase or sale. There was no immediate sale reported.

Key Details

  • Transaction date: June 11, 2026. Report filed with the SEC on June 23, 2026 (appears late relative to the standard two-business-day Form 4 deadline).
  • Grant amounts and reporting price: 30,000 shares @ $0.00 and 182,584 shares @ $0.00 (total 212,584 derivative shares).
  • Shares owned after transaction: not disclosed in the information provided in this summary.
  • Vesting/footnotes:
    • Footnote 1: The 30,000-share award vests on the earlier of (a) June 11, 2027 or (b) the next annual meeting of stockholders after the grant date.
    • Footnote 2: The 182,584-share award vests in equal quarterly increments through June 11, 2027, with the first increment vesting September 11, 2026.
  • Transaction type code on Form 4: A = Award/Grant (derivative).

Context
These are derivative awards (likely options or restricted stock units) with specified vesting schedules; they do not represent immediately tradable shares and there is no indication in the filing that any shares were sold or that a cashless exercise occurred. Awards can indicate compensation or retention incentives rather than a direct endorsement of near‑term stock direction. The filing date suggests the Form 4 was submitted after the typical two-business-day window, which is noteworthy for compliance/timeliness but does not by itself imply anything about company performance.